Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
FDA seeks input on Makary’s voucher pilot
The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated



